# Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

> **NCT07214532** · NA · RECRUITING · sponsor: **Natera, Inc.** · enrollment: 725 (estimated)

## Conditions studied

- Breast Neoplasms
- Carcinoma, Ductal, Breast
- Receptors, Estrogen (for ER-positive Requirement)

## Interventions

- **DEVICE:** ctDNA-Guided Treatment Strategy

## Key facts

- **NCT ID:** NCT07214532
- **Lead sponsor:** Natera, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2037-11-15
- **Final completion:** 2037-12-30
- **Target enrollment:** 725 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214532, "Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07214532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*